LRI Investments’s TG Therapeutics TGTX Stock Holding History

LRI Investments’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100	Closed	-$1.78K	–	1201
2024 Q2	$1.78K	Hold	100	–	–	﹤0.01%	1066
2024 Q1	$1.52K	Buy	+100	New	+$1.59K	﹤0.01%	769

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LRI Investments's TGTX Position: Q3 2024 in Review

LRI Investments sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 100 shares — an estimated $1.78K sold.

LRI Investments first reported a position in TGTX in Q1 2024 and held it in 2 quarters. The position peaked at $1.78K in Q2 2024. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

LRI Investments reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
LRI Investments sold 100 TG Therapeutics shares in Q3 2024, an estimated $1.78K.
LRI Investments first reported a position in TG Therapeutics in Q1 2024 and held it in 2 quarters.
LRI Investments's TG Therapeutics position peaked at $1.78K in Q2 2024.
308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on LRI Investments's 13F filing for Q3 2024, filed 15 Nov 2024.